Usage of the 3 classes of markers together with targeted drugs is the essence of precision oncology. Biomarkers can be DNA derived from normal tissue, RNA derived from tumor tissue, protein derived from blood, and metabolotome derived from urine for example.
The major clinical challenges in bladder cancer include:
- Optimization of surveillance of non-muscle invasive bladder cancer (NMIBC) and try to predict natural history, including recurrence and progression.
- Reduction of mortality of muscle invasive bladder cancer (MIBC) / metastatic disease. It is important to identify patients with occult nodal metastasis. It is also important to identify high risk patients that are also responders to systemic therapy. Lastly, it is crucial to recognize therapeutic targets and new drugs.
In summary, Dr. Theodorescu reiterated the importance of molecular profiling of patients at high risk for bladder cancer, enabling us to administer molecular guided therapy, and molecularly perform guided follow-up.
Presented By: Dan Theodorescu, MD, University of Colorado, Comprehensive Cancer Center, Aurora, CO
Written By: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre
at the 2017 Bladder Cancer Academy - June 9 - 10 - Schaumburg, Illinois, USA